Your Messages Inbox
Your Article Summary
See Latest ArticlesCell Therapeutics Initiating Rolling NDA Submission for Pixantrone
Cell Therapeutics, 04/15/09
Cell Therapeutics, Inc. announced that it began a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma. CTI expects to complete the submission this quarter and will request priority review which if granted could lead to an approval decision from the FDA in Q4 2009.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor